Source: BioSpace
Area: News
According to a Biospace report, positive phase III data have been reported for Omeros' experimental ocular drug, OMS302. The drug is a combination of the anti-inflammatory agent ketorolac and the mydriatic agent phenylephrine and is intended for the maintenance of mydrioasis (pupil dilation) and reduction of post-operative pain during cataract and other lens replacement surgery.
The multicenter, double-blind, phase III clinical trial randomised 405 patients to either OMS302 or placebo. The primary endpoint, maintenance of intraoperative mydriasis, which is critical to the safety and surgical (Read more...)
Uncategorized